Evidence map›Paper›PMID 29920129›Full record

ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2018

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.

Patricia A Young, Reiko E Yamada, Kham R Trinh, Alex Vasuthasawat, Satiro De Oliveira, Douglas H Yamada, Sherie L Morrison, John M Timmerman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Patricia A Young1 Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Reiko E Yamada1 Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Kham R Trinh2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California.
Alex Vasuthasawat2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California.
Satiro De Oliveira3 Division of Pediatric Hematology & Oncology, Department of Pediatrics, University of California, Los Angeles, Los Angeles, California.
Douglas H Yamada2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California.
Sherie L Morrison2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California.
John M Timmerman1 Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
University of California, Los Angeles · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MITSUYASU, RONALD T. · 1991 to 2018
$39.9M
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myelomaR01CA200910 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORRISON, SHERIE L · 2016 to 2020
$1.8M
Antibody-interferon fusion proteins for treatment of B-cell malignanciesR01CA162964 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORRISON, SHERIE L · 2011 to 2015
$1.6M
Engineering Precision Medicine to Enhance Graft-Versus-Lymphoma EffectK23CA222659 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DE OLIVEIRA, SATIRO NAKAMURA · 2017 to 2022
$920k
NCI NIH HHS K23 CA222659NCI NIH HHS R01 CA162964NCI NIH HHS R01 CA200910NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

An important emerging form of immunotherapy targeting B cell malignancies is chimeric antigen receptor (CAR) T cell therapy. Despite encouraging response rates of anti-CD19 CAR T cell therapy in B cell lymphomas, limited durability of response necessitates further study to potentiate CAR T cell efficacy. Antibody-targeted interferon (IFN) therapy is a novel approach in immunotherapy. Given the ability of IFNs to promote T cell activation and survival, target cell recognition, and cytotoxicity, we asked whether antibody-targeted IFN could enhance the antitumor effects of anti-CD19 CAR T cells. We produced an anti-CD20-IFN fusion protein containing the potent type 1 IFN isoform alpha14 (α14), and demonstrated its ability to suppress proliferation and induce apoptosis of human B cell lymphomas. Indeed, with the combination of anti-CD20-hIFNα14 and CAR T cells, we found enhanced cell killing among B cell lymphoma lines. Importantly, for all cell lines pretreated with anti-CD20-hIFNα14, the subsequent cytokine production by CAR T cells was markedly increased regardless of the degree of cell killing. Thus, several activities of CD19 CAR T cells were enhanced in the presence of anti-CD20-hIFNα14. These data suggest that antibody-targeted IFN may be an important novel approach to improving the efficacy of CAR T cell therapy.

Indexed as

ImmunotherapyAntigen-Antibody ReactionsAntigens, CD19Cell Line, TumorHumansInterferon-alphaLymphoma, B-CellReceptors, Chimeric AntigenT-LymphocytesAntigens, CD19Interferon-alphaReceptors, Chimeric AntigenCAR T cellscytokine releasefusion proteinimmunotherapyinterferonlymphoma

Identifiers

PMID29920129
PMCPMC6007814
OpenAlexW2809392500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.